Jun 2026 (Q2 FY26) — Jul 30, 2026
Neurocrine Biosciences Q2 FY26 — Record Sales and Pipeline Advancement
Read the full callNeurocrine Biosciences (NBIX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Neurocrine Biosciences earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 959 | +39.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 15.8 | −5.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 144 | +34.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$136.98 +0.94% · +$1.27
Performance −2.2% 1Y
1Y: $140.09 on 17 Oct 2025 → $136.98. High $185.5 (30 Jul 2026), low $123.1 (12 Feb 2026).
- Previous close
- $135.71
- 52-week range
- $123.1 – $185.5
- One year
- −3.08%
Overview
- Symbol
- NBIX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
Neurocrine Biosciences Q1 FY26 — Record Sales and Robust Pipeline Advancement
Read the full callEvery analysed call
Neurocrine Biosciences earnings calls (NBIX)
Financials
What the filings say
Net profit, year on year: +34% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 622 | 628 | 573 | 688 | 795 | 806 | 815 | 959 |
| Expenses | 438 | 486 | 549 | 542 | 556 | 595 | 621 | 808 |
| Operating profit | 184 | 142 | 24 | 146 | 239 | 211 | 193 | 152 |
| Operating margin | 29.6% | 22.6% | 4.1% | 21.2% | 30.1% | 26.2% | 23.7% | 15.8% |
| Other income | 7 | 21 | -9 | 14 | 53 | 29 | 53 | 11 |
| Interest | — | — | — | 0 | — | — | — | 3 |
| Profit before tax | 190 | 163 | 15 | 160 | 292 | 239 | 247 | 162 |
| Tax rate | 31.8% | 36.6% | 46.3% | 32.6% | 28.2% | 35.8% | 19.8% | 11.0% |
| Net profit | 130 | 103 | 8 | 108 | 210 | 154 | 198 | 144 |
| EPS ($ per share) | 1.28 | — | 0.08 | 1.09 | 2.11 | — | 1.97 | 1.43 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -1,178 | -1,133 | -725 | -636 | -407 | -157 | 29 | 448 |
| Total liabilities | 512 | 669 | 609 | 699 | 661 | 1,019 | 1,129 | 1,378 |
| Fixed assets | 34 | 42 | 45 | 59 | 59 | 71 | 83 | 90 |
| Investments | 509 | 558 | 614 | 371 | — | — | — | — |
| Total assets | 993 | 1,306 | 1,735 | 2,073 | 2,369 | 3,251 | 3,719 | 4,632 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 101 | 147 | 229 | 257 | 339 | 390 | 595 | 783 |
| Cash from investing | -243 | -211 | 4 | -130 | -177 | -467 | -127 | -264 |
| Cash from financing | 30 | 32 | -158 | 27 | -234 | 65 | -487 | -38 |
| Net cash flow | -112 | -32 | 75 | 154 | -73 | -12 | -18 | 480 |
| Capital expenditure | -25 | -15 | -11 | -23 | -16 | -28 | -38 | -34 |
| Free cash flow | 77 | 132 | 218 | 233 | 323 | 362 | 557 | 749 |
NBIX revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Reportable | — | — | 100% | 100% | 100% | 100% | 100% | 100% | +39.5% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
197 filings between Nov 1, 2025 and Sep 14, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$76.97M
39 sales by 15 insiders
97% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 20
- Award — granted as compensation
- 75
- Option exercise — converted options into shares
- 57
- Tax withheld — shares kept back by the company to cover tax
Also filed: 6 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| GORMAN KEVIN CHARLES | — | $37.82M | May 19, 2026 |
| Cooke Julie | — | $5.77M | Jun 2, 2026 |
| Gano Kyle | — | $4.87M | Jan 16, 2026 |
| Lippoldt Darin | — | $4.20M | Jul 9, 2026 |
| SHERWIN STEPHEN A | — | $4.13M | Jun 5, 2026 |
| Delaet Ingrid | — | $3.75M | Jul 10, 2026 |
| Onyia Jude | — | $3.47M | Jun 1, 2026 |
| RASTETTER WILLIAM H | — | $2.73M | Nov 5, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Boyer David W. Chief Corp. Affairs Officer | Sale 10b5-1 plan | 826 | $130.1K |
| Sep 14, 2026 | ABERNETHY MATT Chief Financial Officer | Sale 10b5-1 plan | 2,311 | $363.3K |
| Sep 11, 2026 | ABERNETHY MATT Chief Financial Officer | Award 10b5-1 plan | 5,020 | $0 |
| Sep 11, 2026 | Boyer David W. Chief Corp. Affairs Officer | Award 10b5-1 plan | 3,587 | $0 |
| Sep 11, 2026 | Boyer David W. Chief Corp. Affairs Officer | Tax withheld 10b5-1 plan | 1,936 | $302.4K |
| Sep 11, 2026 | Keswani Sanjay Chandru Chief Medical Officer | Tax withheld | 2,112 | $329.9K |
| Sep 11, 2026 | GORMAN KEVIN CHARLES Director | Award | 14,343 | $0 |
| Sep 11, 2026 | Gano Kyle Chief Executive Officer | Tax withheld | 3,386 | $529.0K |
| Sep 11, 2026 | Cooke Julie Chief Human Resources Officer | Award | 3,587 | $0 |
| Sep 11, 2026 | ABERNETHY MATT Chief Financial Officer | Tax withheld 10b5-1 plan | 2,709 | $423.2K |
| Sep 11, 2026 | Onyia Jude Chief Scientific Officer | Award | 3,587 | $0 |
| Sep 11, 2026 | Lippoldt Darin Chief Legal Officer | Award | 4,483 | $0 |
| Sep 11, 2026 | Lippoldt Darin Chief Legal Officer | Tax withheld | 2,419 | $377.9K |
| Sep 11, 2026 | GORMAN KEVIN CHARLES Director | Tax withheld | 7,839 | $1.22M |
| Sep 11, 2026 | Gano Kyle Chief Executive Officer | Tax withheld | 994 | $155.3K |
| Sep 11, 2026 | BENEVICH ERIC Chief Commercial Officer | Tax withheld | 3,386 | $529.0K |
| Sep 11, 2026 | Keswani Sanjay Chandru Chief Medical Officer | Award | 3,914 | $0 |
| Sep 11, 2026 | Cooke Julie Chief Human Resources Officer | Tax withheld | 1,936 | $302.4K |
| Sep 11, 2026 | Gano Kyle Chief Executive Officer | Award | 1,842 | $0 |
| Sep 11, 2026 | Delaet Ingrid Chief Regulatory Officer | Tax withheld | 2,419 | $377.9K |
| Sep 11, 2026 | Delaet Ingrid Chief Regulatory Officer | Award | 4,483 | $0 |
| Sep 11, 2026 | BENEVICH ERIC Chief Commercial Officer | Award | 6,275 | $0 |
| Sep 11, 2026 | Gano Kyle Chief Executive Officer | Award | 6,275 | $0 |
| Sep 11, 2026 | Onyia Jude Chief Scientific Officer | Tax withheld | 1,936 | $302.4K |
| Sep 9, 2026 | BENEVICH ERIC Chief Commercial Officer | Option exercise 10b5-1 plan | 3,194 | $138.1K |
| Sep 9, 2026 | BENEVICH ERIC Chief Commercial Officer | Sale 10b5-1 plan | 2,154 | $333.0K |
| Sep 2, 2026 | SHERWIN STEPHEN A Director | Gift | 1,000 | $0 |
| Aug 4, 2026 | Onyia Jude Chief Scientific Officer | Gift | 2,409 | $0 |
| Jul 29, 2026 | Norwalk Leslie V Director | Option exercise 10b5-1 plan | 842 | $117.4K |
| Jul 28, 2026 | Norwalk Leslie V Director | Sale 10b5-1 plan | 1,250 | $227.5K |
| Jul 10, 2026 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 plan | 4,367 | $790.5K |
| Jul 10, 2026 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 plan | 4,367 | $463.0K |
| Jul 9, 2026 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 plan | 10,000 | $1.80M |
| Jul 9, 2026 | Lippoldt Darin Chief Legal Officer | Option exercise 10b5-1 plan | 10,000 | $814.9K |
| Jul 9, 2026 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 plan | 8,433 | $873.0K |
| Jul 9, 2026 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 plan | 8,433 | $1.51M |
| Jul 8, 2026 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 plan | 2,737 | $488.7K |
| Jul 8, 2026 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 plan | 2,737 | $283.3K |
| Jul 7, 2026 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 plan | 3,401 | $352.1K |
| Jul 7, 2026 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 plan | 3,401 | $607.3K |
| Jun 29, 2026 | Lippoldt Darin Chief Legal Officer | Option exercise 10b5-1 plan | 8,110 | $660.9K |
| Jun 29, 2026 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 plan | 1,690 | $288.7K |
| Jun 29, 2026 | Lippoldt Darin Chief Legal Officer | Option exercise 10b5-1 plan | 1,690 | $137.7K |
| Jun 29, 2026 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 plan | 8,110 | $1.38M |
| Jun 26, 2026 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 plan | 200 | $33.9K |
| Jun 26, 2026 | Lippoldt Darin Chief Legal Officer | Option exercise 10b5-1 plan | 200 | $16.3K |
| Jun 5, 2026 | SHERWIN STEPHEN A Director | Option exercise 10b5-1 plan | 15,000 | $804.6K |
| Jun 5, 2026 | SHERWIN STEPHEN A Director | Sale 10b5-1 plan | 6,896 | $1.14M |
| Jun 5, 2026 | Onyia Jude Chief Scientific Officer | Gift | 2,441 | $0 |
| Jun 5, 2026 | SHERWIN STEPHEN A Director | Sale 10b5-1 plan | 1,843 | $308.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for NEUROCRINE BIOSCIENCES INC
Free account. Everything above stays public.
Write why you follow NEUROCRINE BIOSCIENCES INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading